Haldol

Haldol is the brand name for the antipsychotic medication haloperidol, supplied in oral dosage form with strength not specified. It belongs to the butyrophenone class of typical antipsychotics and is marketed in the European Union as a prescription‑only product. Haloperidol works primarily as a dopamine D2 receptor antagonist, which helps manage various psychotic and movement‑related conditions. It is used under medical supervision and requires individualized dosing based on clinical response.

Haloperidol (Haldol) is indicated for several psychiatric and neurological conditions where dopamine blockade is therapeutic.

- Management of schizophrenia, both chronic maintenance and acute exacerbations. - Treatment of acute psychosis of various etiologies, such as drug‑induced or brief psychotic disorder. - Control of manic episodes in bipolar disorder when rapid symptom reduction is needed. - Rapid calming of severe agitation or aggression in emergency or inpatient settings. - Reduction of motor and vocal tics in Tourette syndrome and other tic disorders. - Adjunctive therapy for severe behavioral disturbances in patients with neurodevelopmental disorders.

Haloperidol may cause a range of adverse effects that vary in frequency and severity.

Common: - Drowsiness or sedation, especially when therapy is initiated. - Extrapyramidal symptoms such as tremor, rigidity, akathisia, or dystonia. - Dry mouth and increased salivation, which may affect oral comfort. - Constipation or gastrointestinal discomfort, including nausea. - Blurred vision or dizziness, often transient. - Weight gain or changes in appetite, varying among individuals.

Serious: - Neuroleptic malignant syndrome, a rare but potentially fatal reaction characterized by fever, muscle rigidity, and autonomic instability. - Tardive dyskinesia, persistent involuntary movements that may become irreversible. - Severe hypotension or cardiac arrhythmias, particularly in patients with pre‑existing heart disease. - Seizures or worsening of pre‑existing seizure disorders, requiring monitoring. - Elevated prolactin levels leading to menstrual disturbances, galactorrhea, or sexual dysfunction. - Severe allergic reactions such as rash, angioedema, or anaphylaxis, requiring immediate medical attention.

When prescribing haloperidol, clinicians should consider several precautionary measures to minimize risk and ensure safe use.

- Assess cardiovascular status, as haloperidol can cause QT prolongation and hypotension. - Evaluate for a history of movement disorders, including Parkinson’s disease or prior extrapyramidal reactions. - Use the lowest effective dose, especially in elderly patients, to reduce sedation and fall risk. - Monitor for signs of neuroleptic malignant syndrome, particularly during dose escalation. - Check prolactin levels periodically in patients who develop hormonal symptoms. - Avoid use during pregnancy unless benefits outweigh risks, due to limited safety data. - Review liver and kidney function, as impairment may affect drug clearance.

Haloperidol can interact with other medications, altering its efficacy or increasing adverse effect potential.

Avoid: - Concurrent use with other strong dopamine antagonists, which may intensify extrapyramidal symptoms. - Combination with medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Co‑administration with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels.

Use with caution: - Concurrent use of CNS depressants (e.g., benzodiazepines, opioids) may increase sedation and respiratory depression. - Combining with anticholinergic agents can mask early signs of extrapyramidal side effects. - Use alongside drugs that affect hepatic metabolism (e.g., carbamazepine, rifampin) may reduce haloperidol effectiveness.